As a pioneer in digital pathology, NeoGenomics has expanded its partnership with Indica Labs, leveraging its Halo AP® platform via a scalable, cloud-based framework. As computational pathology and AI-driven insights reshape healthcare, NeoGenomics continues to broaden its menu of advanced tools to guide personalized treatment decisions for the patients its clients serve.
The same trusted tests you rely on, now offering broader genomic coverage, increased reporting sensitivity, and faster turnaround times
MRD detection, personalized to every patient’s tumor. Wherever the signal starts, find it with RaDaR ST. Now covered by Medicare for (HR+) positive/HER2 negative breast cancer, HPV negative head and neck cancer, and immunotherapy.
Our technology and test offerings are constantly evolving to offer state-of-the-art capabilities in cancer testing that align to the latest evidence and guidelines.
NeoGenomics provides unparalleled client support to help providers diagnose and choose the right therapy selection testing to address gaps in cancer care.
With over a decade of experience, NeoGenomics has contributed to a wealth of research, uncovering insights to advance breakthroughs in cancer diagnostics. Our expertise in real-world evidence (RWE) and genomic insights helps shape the future of precision medicine diagnostics.
